Raadpleeg ook:

https://kanker-actueel.nl/NL/studiepublicaties-van-niet-toxische-middelen-en-behandelingen-uit-literatuurlijst-van-arts-bioloog-drs-engelbert-valstar-gerelateerd-aan-vormen-van-darmkanker.html

31 januari 2019: Bron: World J Gastroenterol. 2017 Nov 14; 23(42): 7618–7625.

Opnieuw bewijst een grote studie dat TCM - Traditionele Chinese Medicijnen / Kruiden voor darmkankerpatienten een grote meerwaarde kan betekenen. Hier gaat het om een studie onder 817 darmkankerpatienten met operabele darmkanker stadium I / II / III waarin ook is onderzocht wat het verschil in effect en ziektevrije tijd is tussen rechts en links liggende darmkankertumoren.

Overall blijken TCM - Chinese kruiden mits 6 maanden gebruikt voor een verschil op 6-jaars ziektevrije tijd te geven van 15 procent in vergelijking met geen TCM gebruik. Overall blijkt dat onder de TCM gebruikers met tumoren die links zaten na 6 jaar 56,95 procent nog steeds ziektevrij was tegenover 41,50 procent in de groep die geen TCM - Traditionele Chinese Medicijnen hadden gebruikt.

Voor patienten waar de darmtumoren rechts lagen is dat verschil ook 15 procent in het voordeel van TCM gebruik maar bleken minder patienten ziektevrij op 6 jaar namelijk 52,92 vs 37,19 procent respectievelijk. Statistisch was er dus nauwelijks verschil tussen de tumoren die rechts of links lagen want verschil blijft 15 procent.

En geen van de darmkankerpatienten had chemo of andere behandeling behalve dan operatie gehad.

Kaplan-Meier disease-free survival curves for all patients.

Lees eens in oncoline (waar de officiele behandelingsrichtlijnen worden gegeven voor alle vormen van kanker) wat de prognose is voor operabele darmkanker dan schrikt u denk ik van de prognoses, zelfs met chemo.

Bedenk dat er een therapeutisch effect van 15 procent is op wel of geen recidief tussen wel of geen TCM gebruik. Welke reguliere behandeling bereikt dat?

Hier het abstract van deze studie: Right- and left-sided colorectal cancers respond differently to traditional Chinese medicine met verwijzingen naar referenties die volledig gratis is in te zien en met gedetailleerde grafieken.

Patients with either LSCRC or RSCC and who took TCM experienced longer DFS; furthermore, patients with RSCC benefited more from TCM in DFS.

. 2017 Nov 14; 23(42): 7618–7625.

Published online 2017 Nov 14. doi: 10.3748/wjg.v23.i42.7618

PMCID: PMC5698254

PMID: 29204061

Right- and left-sided colorectal cancers respond differently to traditional Chinese medicine

Shan-Shan Liu, Qi Shi, Hong-Jia Li, Wei Yang, Su-Su Han, Shao-Qi Zong, Wen Li, and Feng-Gang Hou

Author information Article notes Copyright and License information Disclaimer

Abstract

AIM

To explore the differences in the responses of left-sided colorectal cancer (LSCRC) and right-sided colon cancer (RSCC) to traditional Chinese medicine (TCM).

METHODS

Patients with postoperative stage I-III colorectal cancer (CRC) were enrolled and divided into the LSCRC with or without TCM and RSCC with or without TCM groups depending on the primary tumor side and TCM administration. Patients in the TCM group were given TCM for at least 6 mo. Our research adopted disease-free survival (DFS) as the primary endpoint. We applied a Cox proportional hazards regression model for the multivariate factor analysis using Stata 12.0 and SPSS 22.0 software for data analysis.

RESULTS

Of the 817 patients included in our study, 617 had LSCRC (TCM group, n = 404; Non-TCM group, n = 213), and 200 had RSCC (TCM group, n = 132; Non-TCM group, n = 68). The 6-year DFS for patients with LSCRC was 56.95% in the TCM group and 41.50% in the Non-TCM group (P = 0.000). For patients with RSCC, the 6-year DFS was 52.92% in the TCM group and 37.19% in the Non-TCM group (P = 0.003). Differences between LSCRC and RSCC were not statistically significant regardless of TCM ingestion.

CONCLUSION

Patients with either LSCRC or RSCC and who took TCM experienced longer DFS; furthermore, patients with RSCC benefited more from TCM in DFS.

Research perspectives

Recent studies have proposed that location of primary tumor was related to recurrence, metastasis and the therapeutic effect. The author’s results indicated that patients with LSCRC and RSCC responded differently to TCM; those with RSCC benefited more from TCM than those with LSCRC. Thus, TCM was recommended to postoperative patients with CRC of both sides, especially the right side. In the future research, CRC should be treated separately based on the primary tumor sides.

Go to:

Footnotes

Manuscript source: Unsolicited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: China

Peer-review report classification

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

Institutional review board statement: The study was reviewed and approved by IRB of Shuguang Hospital affiliated with Shanghai University of TCM.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: All authors have declared no conflicts of interest.

Data sharing statement: No additional data were available.

Peer-review started: July 5, 2017

First decision: August 30, 2017

Article in press: September 26, 2017

P- Reviewer: Jeong KY, Mavridis K, Liao KF S- Editor: Chen K L- Editor: A E- Editor: Ma YJ

Go to:

Contributor Information

Shan-Shan Liu, Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.

Qi Shi, Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.

Hong-Jia Li, Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.

Wei Yang, Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.

Su-Su Han, Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.

Shao-Qi Zong, Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.

Wen Li, Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.

Feng-Gang Hou, Oncology Department of Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China. nc.hs.yzs@7211.

Go to:

References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. [PubMed]

2. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–193. [PubMed]

3. Wilhelmsen M, Kring T, Jorgensen LN, Madsen MR, Jess P, Bulut O, Nielsen KT, Andersen CL, Nielsen HJ. Determinants of recurrence after intended curative resection for colorectal cancer. Scand J Gastroenterol. 2014;49:1399–1408. [PubMed]

4. Adams M, Jewell AP. The use of Complementary and Alternative Medicine by cancer patients. Int Semin Surg Oncol. 2007;4:10. [PMC free article] [PubMed]

5. Li W, Li C, Zheng H, Chen G, Hua B. Therapeutic targets of Traditional Chinese Medicine for colorectal cancer. J Tradit Chin Med. 2016;36:243–249. [PubMed]

6. Shi Q, Liu S, Li W, Zong S, Han S, Yang W, Li H, Hou F. Exploring the medication duration based on the effect of traditional Chinese medicine on postoperative stage I-III colorectal patients: a retrospective cohort study. Oncotarget. 2017;8:13488–13495. [PMC free article] [PubMed]

7. Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98. [PubMed]

8. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H; Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53:57–64. [PubMed]

9. Hansen IO, Jess P. Possible better long-term survival in left versus right-sided colon cancer - a systematic review. Dan Med J. 2012;59:A4444. [PubMed]

10. Lu HJ, Lin JK, Chen WS, Jiang JK, Yang SH, Lan YT, Lin CC, Chang SC, Teng HW. Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy. Asia Pac J Clin Oncol. 2016;12:207–215. [PubMed]

11. Tao L, Zhu YJ, Lu XM, Gu Y, Zhao AG, Zheng J, Fu CG, Yang JK. [Clinical study on survival benefit for elderly patients with resected stage II or III colorectal cancer based on traditional Chinese medicine syndrome differentiation and treatment] Zhong Xi Yi Jie He Xue Bao. 2010;8:1159–1164. [PubMed]

12. Zhou LY, Shan ZZ, You JL. Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine. Chin J Integr Med. 2009;15:107–111. [PubMed]

13. Shi Q, Li W, Le QQ, Chen WT, Ren JL, Li Q, Hou FG. Attenuated effects of Jianpi Qushi herbs on patients receiving FOLFOX4 after colorectal cancer surgery: A meta-analysis. Chin J Integr Med. 2016:1–10. [PubMed]

14. Li YR, Chen YQ, Wang H, Zhu P, Chen HJ, Yang BL, Gu YF. Meta - analysis of Chemotherapy Combined with Traditional Chinese Medicine Decoction in Cellular Immunity of Patients with Colorectal Cancer. Liaoning Journal of Traditional Chinese Medicine. 2016;43:2035–2041.

15. Qu YL, Yue GJ, Li JS, Huang H. Effect of Jinlong Capsules on Reversing Paclitaxel-resistance Vincritine-resistance and Enhancing Sensitivity in Human Cancer Cell Lines. Cancer Research on Prevention and Treatment. 2014;41:884–887.

16. Zhu YD. Clinical research on reducing recurrence and metastasis of II, III period colorectal cancer in the integrative medicine. Zhongguo Zhongliu Fangzhi Zazhi. 2016;23:212–213.

17. Qi YM, Wu SS, Shen MH, Ruan SM, Wu S, Guo KB, Huang AQ. Meta - analysis of TCM Therapy Combined with Chemotherapy on Survival Time of Patients with Colorectal Cancer at Stages III - IV. Zhongguo Zhongyiyao Keji Zazhi. 2014;32:2835–2838.

18. Venook A, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney M, O’Neil B, Shaw JE, Polite B, Hochster H, Atkins JN, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) J Clin Oncol. 2014;32:LBA 3.

19. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2000;355:1745–1750. [PubMed]

20. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113:779–788. [PubMed]

21. Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015;21:5167–5175. [PMC free article] [PubMed]

22. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61:847–854. [PMC free article] [PubMed]

23. Chang LC, Yu YL. Dietary components as epigenetic-regulating agents against cancer. Biomedicine (Taipei) 2016;6:2. [PMC free article] [PubMed]

24. Padma VV. An overview of targeted cancer therapy. Biomedicine (Taipei) 2015;5:19. [PMC free article] [PubMed]

25. Zhang M, Zhu WF, Ji Q, Sun Z, Zhou Y, Zhang M, Peng SH. Research Progress of DNA Demethylation of Anti-tumor Traditional Chinese Medicines. Zhongguo Shiyan Fangjixue Zazhi. 2015;21:224–229.

26. Liu XF, Jin HY, Ding YJ, Lu Y, Li L, Ding SQ, Liu F, Ni M, Wang J. Inhibitory effect of Chinese herbs with anti-mutation activity on a mismatch-repair-gene-deficient colorectal cancer cell line. Shijie Huaren Xiaohua Zazhi. 2007;15:2201–2204.

27. Ho TF, Chang CC. A promising “TRAIL” of tanshinones for cancer therapy. Biomedicine (Taipei) 2015;5:23. [PMC free article] [PubMed]

28. Teschke R, Wolff A, Frenzel C, Eickhoff A, Schulze J. Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders. World J Gastroenterol. 2015;21:4466–4490. [PMC free article] [PubMed]

Articles from World Journal of Gastroenterology are provided here courtesy of Baishideng Publishing Group Inc

TCM, Traditionele Chinese Medicijnen, Chinese kruiden, darmkanker, rechts en links liggende darmtumoren, ziektevrije tijd, overall overleving

Plaats een reactie ...

2 Reacties op "TCM - Traditionele Chinese Medicijnen / Kruiden verbeteren ziektevrije tijd met 15 procent voor operabele darmkanker stadium III in vergelijking met geen TCM. Darmtumoren aan linkerkant hadden beste ziektevrije tijd 56 vs 42 procent voor geen TCM"

e.valstar :
31/01/2019
De vraag is of de verdeling steeds at random was. De prognose rechts is altijd minder, wat dus geen nieuws is. Adjuvant chemo geeft in stadium 2 in totaal 24% meer overleving. PSK geeft in stadium B en C een betere overleving (in C 15% meer ook als er al capecitabine of 5-FU met LV is gegeven). Kortom wat zou de verbetering zijn als deze 3 samen in de adjuvant setting worden gegeven. Met alleen chemo als adjuvans ben je er dus niet, maar met TCM alleen ook niet.

Comment
- e.valstar :
  31/01/2019
  Foutje: Stadium 2 in de 2e regel moet stadium 3 zijn.
  
  Comment